top of page

ASGCT 2026: Circio's circular RNA work has been advancing and is furthest along in cardiology indications. $35M in new funding will also help accelerate plans to for the eye, CNS, and in vivo CAR-T

  • May 14
  • 1 min read

Erik Wiklund describes the advantages of circular RNA, and the progress the company has been making since last year's ASGCT. With partnerships and additional funding in hand since then, the company is accelerating its work in multiple dimensions.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page